Lung cancer patients with bone metastases lung cancer, bone metastases,
Conditions
Interventions
Interval of bone modifying agent administration is normal or elongated.
Open-label randomization
Sponsors
TOMONORI MAKIGUCHI
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Target subjects are those who fulfill all of the followings. 1. Those who are 18 years or older diagnosed with lung cancer by histology or cytology. 2. Those who have already received bone modifying agents more than twice. 3. Main organ function is maintained. WBC>3000, Hb>8.0g/dl, Plt 100000/mm3 AST/ALT8.5mg/dl and <11.0mg/dl 4. Those without osteonecrosis of the jaw.
Exclusion criteria
Exclusion criteria: 1. Those whose pain of bone metastases are not well controlled. 2. Those with symptom of spinal cord compression. 3. Those with prognosis are expected to be within 3 months. 4. Those in whom physician consider not appropriate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| change in the bone mineral density 4 months and 8 months later | — |
Secondary
| Measure | Time frame |
|---|---|
| occurence of skeletal related events, osteonecrosis of the jaw, and other adverse events | — |
Contacts
Public ContactMAKIGUCHI TOMONORI
Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine
Outcome results
None listed